Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.53 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.46 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 3/20 | 0.44 |
| ▸ | NOS2 | P35228 | 3/20 | 0.44 |
| ▸ | ARG2 | P78540 | 4/20 | 0.42 |
| ▸ | ARG1 | P05089 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nor-Noha SCHEMBL4097591 | 0.89 | GSR (0.42) | OTCGSRNOS3NOS1NOS2 | |
| Nor-Noha SCHEMBL14754841 | 0.89 | GSR (0.42) | OTCGSRNOS3NOS1NOS2 | |
| SCHEMBL18532015 | 0.86 | OTC (0.53) | OTCDDAH1GSRNOS3NOS1 | |
| Tilarginine SCHEMBL6370536 | 0.84 | OTC (0.51) | OTCDDAH1GSRNOS3NOS1 | |
| SCHEMBL13059111 | 0.84 | OTC (0.51) | OTCDDAH1GSRNOS3NOS1 | |
| SCHEMBL21089964 | 0.84 | OTC (0.51) | OTCDDAH1GSRNOS3NOS1 | |
| Tilarginine SCHEMBL12028766 | 0.84 | OTC (0.51) | OTCDDAH1GSRNOS3NOS1 | |
| Tilarginine SCHEMBL315843 | 0.84 | OTC (0.51) | OTCDDAH1GSRNOS3NOS1 | |
| SCHEMBL25216092 | 0.83 | OTC (0.50) | OTCDDAH1GSRNOS3NOS1 | |
| SCHEMBL8730134 | 0.83 | NOD1 (0.52) | OTCDDAH1GSRNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527196-A4 | TREATMENT FOR ASTHMA OR ALLERGIES | CHILDRENS HOSP MEDICAL CENTER (US) | 2007-03-14 | — | — | EP | claimed |
| EP-1527196-A2 | TREATMENT FOR ASTHMA OR ALLERGIES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2005-05-04 | — | — | EP | claimed |
| WO-2003073990-A2 | TREATMENT FOR ASTHMA OR ALLERGIES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2003-09-12 | — | — | WO | claimed |
| WO-1994016740-A1 | THE USE OF NITRIC OXIDE-DELIVERING COMPOUNDS FOR THE TREATMENT OR PREVENTION OF ALCOHOLIC LIVER INJURY | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1994-08-04 | — | — | WO | claimed |
| EP-3523274-B1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | ORBUS THERAPEUTICS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250255850-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2025-08-14 | — | — | US | disclosed |
| CN-119780447-A | Biomarker for early pregnancy related state of dairy cows and application thereof | 宁夏大学 | 2025-04-08 | — | — | CN | disclosed |
| US-12226425-B2 | Inhibitors of ARG1 and/or ARG2 | ARCUS BIOSCIENCES, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-09-26 | — | — | US | disclosed |
| US-12054500-B2 | Arginase inhibitors | ARCUS BIOSCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4337197-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2024-03-20 | — | — | EP | disclosed |
| US-11931364-B2 | Modulation of the nitric oxide synthase pathway for oral health | MEHARRY MEDICAL COLLEGE (US) | 2024-03-19 | — | — | US | disclosed |
| US-20020006913-A1 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | PRO-NEURON, INC. | 2002-01-17 | — | — | US | disclosed |
| US-20010044421-A1 | Administering to skin a composition containing deoxyribonucleosides in concentrations sufficient to enhance DNA repair or reduce mutation frequency in a vehicle capable of delivering deoxyribonucleosides to skin cells | PRO-NEURON, INC. | 2001-11-22 | — | — | US | disclosed |
| US-20010044419-A1 | Antimutagenic compositions for treatment and prevention of photodamage to skin | PRO-NEURON, INC. | 2001-11-22 | — | — | US | disclosed |
| WO-2001085981-A2 | METHODS FOR STIMULATING NERVOUS SYSTEM REGENERATION AND REPAIR BY REGULATING ARGINASE I AND POLYAMINE SYNTHESIS | RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK (US) | 2001-11-15 | — | — | WO | disclosed |
| US-6255290-B1 | REDUCING SENSITIVITY TO SKIN CANCER; TOPICAL ADMINISTERING OF NUCLEOTIDE | PRO-NEURON, INC. | 2001-07-03 | — | — | US | disclosed |
| US-6028054-A | ORALLY ADMINISTERING PHARMACEUTICAL COMPOUND TO MAMMAL IN NEED OF TREATMENT WITH COMPOUND CONCURRENTLY WITH BIOENHANCER COMPRISING INHIBITOR OF CYTOCHROME P450 3A ENZYME OR INHIBITOR OF P-GLYCOPROTEIN-MEDIATED MEMBRANE TRANSPORT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-02-22 | — | — | US | disclosed |
| WO-2000003721-A1 | IMMUNOSUPPORTIVE DRUG SPARING DIET | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-01-27 | — | — | WO | disclosed |
| WO-1994016740-A1 | THE USE OF NITRIC OXIDE-DELIVERING COMPOUNDS FOR THE TREATMENT OR PREVENTION OF ALCOHOLIC LIVER INJURY | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054500-B2 | Arginase inhibitors | ARG1, ARG2, ARGLU1 | OTC 48/4885DDAH1 233/4885GSR 2236/4885 |
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, SMN1; SMN2 | OTC 10/4885DDAH1 1437/4885GSR 52/4885 |
| US-20250255850-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, PYGB | OTC 9/4885DDAH1 1184/4885GSR 63/4885 |
| US-11931364-B2 | Modulation of the nitric oxide synthase pathway for oral health | TAS2R4, GMPS, BPHL | OTC 1312/4885DDAH1 683/4885GSR 50/4885 |
| US-12226425-B2 | Inhibitors of ARG1 and/or ARG2 | ARG1, ARG2, ARGLU1 | OTC 719/4885DDAH1 706/4885GSR 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.